Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Carbaglu Prior Auth | OpenPayer
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    Carbaglu (carglumic acid) Prior Authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and access requirements for Carbaglu in adult and pediatric patients with acute or chronic hyperammonemia caused by hepatic N-acetylglutamate synthase deficiency.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCarbaglu (carglumic acid) Prior Authorization
    Policy CodePolicy N/A
    Change TypeAdministrative archivalno content revision
    Effective DateJanuary 28, 2014
    Last ReviewAug 3, 2021
    Next Review DateN/A
    Key ActionPrescribers must submit documentation of NAGS deficiency, the related hyperammonemia indication, and metabolic-disorder prescribing experience.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was archived on August 3, 2021 after review with no content revision.

    2Covered treatment settings
    Adult and pediatricPatient populations
    200 mgTablet strength
    AccredoSpecialty pharmacy
    Archived

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy status

    Coverage Criteria

    Initial coverage criteria

    Carbaglu is covered when ALL of the following criteria are met:

    ALL of the following

    • The patient is an adult or pediatric patient requiring adjunctive treatment of acute hyperammonemia or maintenance therapy of chronic hyperammonemia due to a deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS).
    • Carbaglu is prescribed by a physician experienced in the management of metabolic disorders.

      Hyperammonemia is a potentially life-threatening emergency.

    Initial Therapy Criteria

    Initial Carbaglu Authorization

    Initial therapy requires the following:

    Indication and prescriber requirements: Carbaglu is used for adjunctive treatment of acute hyperammonemia or maintenance therapy of chronic hyperammonemia caused by hepatic N-acetylglutamate synthase deficiency, and is prescribed by a physician experienced in the management of metabolic disorders.

    Applies to adult and pediatric patients.

    Provider Actions

    Note

    Covered NAGS Deficiency Indications

    Carbaglu is covered for adjunctive treatment of acute hyperammonemia and for maintenance therapy of chronic hyperammonemia in adult and pediatric patients when due to hepatic N-acetylglutamate synthase (NAGS) deficiency.

    • Acute hyperammonemia: adjunctive treatment
    • Chronic hyperammonemia: maintenance therapy
    • Applies to adult and pediatric patients
    Prior Authorization

    Specialty Pharmacy Access

    Carbaglu is available only by direct shipment from Accredo specialty pharmacy. Prescribers must contact Accredo to initiate patients on this product.

    • Accredo Health Group: 888-454-8860
    • Website: www.accredo.com
    • Not available through pharmaceutical wholesalers or retail pharmacies

    Background

    Carbaglu (carglumic acid) is an analog replacement for N-acetylglutamate in patients with N-acetylglutamate synthase (NAGS) deficiency. NAGS produces N-acetylglutamate, which is required to activate hepatic mitochondrial carbamoyl phosphate synthetase 1, the first enzyme in the urea cycle that converts ammonia into urea. When NAGS is deficient, carglumic acid replaces the missing N-acetylglutamate to support ammonia metabolism. Because hyperammonemia can be potentially life-threatening, treatment should be managed by a physician experienced in metabolic disorders.

    Definitions

    N-acetylglutamate synthase (NAGS)
    DefinitionN-acetylglutamate synthase (NAGS) is a mitochondrial enzyme that produces N-acetylglutamate (NAG).
    Enzyme activationNAG is a required allosteric activator of hepatic mitochondrial carbamoyl phosphate synthetase 1 (CPS 1).
    Urea-cycle roleCPS 1 converts ammonia into urea in the first step of the urea cycle.
    Deficiency contextIn patients with NAGS deficiency, carglumic acid serves as a replacement for NAG.
    Hyperammonemia
    DefinitionHyperammonemia is an accumulation of ammonia in the blood.
    Acute treatment
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCarbaglu (carglumic acid) Prior Authorization
    Policy CodePolicy N/A
    Change TypeAdministrative archivalno content revision
    Effective DateJanuary 28, 2014
    Last ReviewAug 3, 2021
    Next Review DateN/A
    Key ActionPrescribers must submit documentation of NAGS deficiency, the related hyperammonemia indication, and metabolic-disorder prescribing experience.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaProvider ActionsBackgroundDefinitions
    Documentation Required

    Clinical Indication Documentation

    Submit clinical documentation supporting hepatic NAGS deficiency and the applicable covered indication—acute hyperammonemia requiring adjunctive treatment or chronic hyperammonemia requiring maintenance therapy.

    • Document the NAGS deficiency diagnosis.
    • Identify whether treatment is for acute or chronic hyperammonemia.
    • Document the patient’s age category when applicable: adult or pediatric.
    Denial Risk

    Indication Must Be Hepatic NAGS Deficiency

    The requested use must be for hyperammonemia caused by deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). Other causes of hyperammonemia are not included in these covered indications.

    • Covered acute indication: adjunctive treatment of acute hyperammonemia due to hepatic NAGS deficiency.
    • Covered chronic indication: maintenance therapy of chronic hyperammonemia due to hepatic NAGS deficiency.
    Documentation Required

    Qualified Prescriber Required

    Carbaglu must be prescribed by a physician experienced in the management of metabolic disorders, because hyperammonemia is a potentially life-threatening emergency.

    • Verify the prescriber’s experience managing metabolic disorders.
    Under this policy, acute hyperammonemia may be treated with adjunctive therapy when caused by hepatic NAGS deficiency.
    Chronic managementChronic hyperammonemia may be managed with maintenance therapy when caused by hepatic NAGS deficiency.
    Patient populationsThe policy addresses treatment in both adult and pediatric patients.